BioSpace News Archive

Accord BioPharma, Inc. announced today the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for DMB-3115. DMB-3115 is a proposed biosimilar to STELARA®, a blockbuster drug developed by Janssen Biotech, Inc. and approved for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

GrayMatters Health (GMH), developer of digital self-neuromodulation therapies for mental health care, announces the official launch of Prism for PTSD in the United States.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2024 on Thursday, February 1, after the market closes.

Napo Pharmaceuticals announced that the United States Patent and Trademark Office on January 2, 2024 issued a new U.S. patent to Napo for methods for treating congenital diarrheal disorders in patients with an inhibitor of chloride-ion transport such as crofelemer, Napo’s novel plant-based prescription drug.

SELLAS Life Sciences Group, Inc. announced the pricing of its previously announced public offering for the purchase and sale of 12,000,000 shares of common stock and accompanying warrants to purchase up to an aggregate of 12,000,000 shares of common stock at a combined purchase price of $0.75 per share and accompanying warrant, resulting in total gross proceeds of $9.0 million, before deducting placement agent commissions and other estimated offering expenses.

ConcertAI, the leader in oncology predictive and generative AI SaaS Solutions and Real-World Data for healthcare and life sciences, today announced that it will be presenting at the 42nd annual J.P. Morgan Healthcare Conference.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1 p.m. London time (8 a.m. Eastern Time).

MOBILion Systems, Inc., a life science tools and instrumentation company, has partnered with The University of Natural Resources and Life Sciences, Vienna, an Agilent Partner Lab, to install its first MOBIE® instrument in Europe.

SomaLogic, Inc., a leader in proteomics technology, announced that, based on the preliminary vote count provided by its proxy solicitors following the Company’s Special Meeting of Stockholders held earlier today, SomaLogic stockholders voted to approve the transaction with Standard BioTools Inc. .

Human growth hormone has long been used to treat certain medical conditions in children. New research from surgeon-scientists at Hospital for Special Surgery shows that there may be a previously unknown complication.